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Abstract
Homozygous recessive mutations in either EFEMP2 (encoding fibulin-4) or FBLN5 (encoding fibulin-5), critical genes for
elastogenesis, lead to autosomal recessive cutis laxa types 1B and 1A, respectively. Previously, fibulin-4 was shown to bind lysyl
oxidase (LOX), an elastin/collagen cross-linking enzyme, in vitro. Consistently, reported defects in humans with EFEMP2
mutations are more severe and broad in range than those due to FBLN5 mutations and encompass both elastin-rich and
collagen-rich tissues. However, the underlying diseasemechanism in EFEMP2mutations has not been fully addressed. Here, we
show that fibulin-4 is important for the integrity of aortic collagen in addition to elastin. Smoothmuscle-specific Efemp2 loss in
mouse (termed SMKO) resulted in altered fibrillar collagen localization with larger, poorly organized fibrils. LOX activity was
decreased in Efemp2-null cells, and collagen cross-linking was diminished in SMKO aortas; however, elastin cross-linking was
unaffected and the level of mature LOX was maintained to that of wild-type aortas. Proteomic screening identified multiple
proteins involved in procollagen processing and maturation as potential fibulin-4-binding partners. We showed that fibulin-4
binds procollagen C-endopeptidase enhancer 1 (Pcolce), which enhances proteolytic cleavage of the procollagen C-terminal
propeptide during procollagen processing. Interestingly, however, procollagen cleavage was not affected by the presence or
absence of fibulin-4 in vitro. Thus, our data indicate that fibulin-4 serves as a potential scaffolding protein during collagen
maturation in the extracellular space. Analysis of collagen in other tissues affected by fibulin-4 loss should further increase our
understanding of underlying pathologic mechanisms in patients with EFEMP2 mutations.
Introduction
Mutations in EGF-containing fibulin-like extracellular matrix
(ECM) protein 2 (EFEMP2), also known as fibulin-4, lead to
autosomal recessive cutis laxa type 1B (ARCL1B; OMIM no.
614437). ARCL1B is characterized by a severe and diverse array
of defects including aortic aneurysms and arterial tortuosity,
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vessel stenosis, cutis laxa, skeletal and craniofacial anomalies,
joint laxity, respiratory problems including diaphragm abnormal-
ities and bradycardia (1–4). Fibulin-4 plays a critical role in elasto-
genesis in vitro (5–7), and conventional knockout of fibulin-4
in mice leads to severe disruption of elastic fiber assembly and
perinatal lethality due to large ascending aortic aneurysms (8).
Although both smooth muscle-specific fibulin-4 knockout mice
and haploinsufficient mice are viable, these mice also develop
ascending aortic aneurysms and vessel tortuosity (9,10). Interest-
ingly, some of the observed phenotypes due to loss of fibulin-4
in humans, including bone fragility and other skeletal abnormal-
ities, documented in multiple reports (1,2,4,11,12), may not be ex-
plained by the loss of elastic fibers alone, raising the question as to
whether fibulin-4 has additional, extra-elastogenic functions (4).
The striking phenotypic differences in patients with EFEMP2
mutations compared with mutations in FBLN5, encoding fibulin-5,
further support the idea of extra-elastogenic roles for fibulin-4.
Both fibulin-4 and fibulin-5 play critical, non-redundant roles in
elastogenesis (6,13), and the phenotypes observed in patients with
mutations in either gene are recapitulated in knockoutmousemod-
els (8,14,15). Although FBLN5 mutations also lead to cutis laxa and
disruption of elastic fibers, these mutations do not result in aortic
aneurysm formation (OMIM no. 219100, ARCL1A). Thus, phenotypic
comparison of EFEMP2 and FBLN5 mutations in patients, and in
corresponding mouse models, strongly suggests that elastic fiber
defects alone are insufficient to drive aneurysm formation. This
notion is consistent with otherswho have hypothesized that fibu-
lin-4 may have extra-elastogenic functions based on a broader
array of proteins that bind fibulin-4 compared with fibulin-5 (16).
Such extra-elastogenic roles for fibulin-4 and their implications
for disease pathogenesis have not been investigated to date.
Several lines of evidence suggest that fibulin-4 may have a
role in regulating collagen in addition to elastin. First,fibulin-4 in-
teracts directly with pro-lysyl oxidase (LOX), an essential enzyme
for elastin and collagen cross-linking (6,7). Second, Efemp2-null
mice bear phenotypic similarities to Lox-null mice, and collagen
abnormalities have been reported in the latter (17). These data
suggest that fibulin-4 may be biologically relevant to collagen
synthesis and maturation. Third, fibulin-4 deficiency results in
increased trichrome staining for collagen in both mice and hu-
mans (1,9), indicating altered collagen synthesis. Finally, de-
creased collagen bundle size was observed in the dermis of a
patient with a homozygous recessive mutation in EFEMP2, sug-
gesting defective collagen fibrillogenesis (4). However, neither
the biosynthesis of collagen, nor the maturation of collagen has
been investigated in these mouse models.
Collagen synthesis, secretion, processing and assembly into
fibrils is a complex, multi-step process (reviewed in 18–20). Brief-
ly, collagen undergoes a number of post-translational modifica-
tions in the endoplasmic reticulum, including hydroxylation
of lysine and proline residues, and is folded via the help of
collagen-specific chaperones including SERPINH1, FKBP65 and
foldases (21,22). Once secreted, the N- and C-terminal propep-
tides are cleaved by specific enzymes [ADAMTS proteases and
tolloid metalloproteases including bone morphogenic protein 1
(BMP1), respectively], andmature collagenmolecules self-assemble
to form a fibril (18). After extensive post-translational modifi-
cations, additional molecules including small leucine-rich pro-
teoglycans (SLRPs) regulate fibril growth (18). LOX catalyzes the
reaction of oxidative deamination on the telopeptidyl lysine
and hydroxylysine residues of collagen to initiate covalent in-
termolecular cross-linking. Disruption of any of these steps of
collagen biosynthesis and maturation has been shown to affect
the quantity and quality of collagen matrix.
Multiple studies have demonstrated the importance of colla-
gen in maintaining vascular wall integrity. For instance, a de-
crease in type I collagen due to a deletion in first intron of the
Col1a1 gene leads to aortic dissection and rupture in mice in
the absence of aortic dilatation (23–25). Also, mice haploinsuffi-
cient for Col3a1 due to a spontaneous 185 kb deletion in the
gene die from aortic rupture at 4–10 weeks with a median age
of 6 weeks (26). These studies and others highlight the critical in-
volvement of fibrillar collagen in aortic disease, particularly aor-
tic dissection and rupture. Here, we show that the loss of fibulin-4
in smooth muscle cells (SMCs) leads to previously uncharacter-
ized molecular defects in collagen biosynthesis. Since aortic an-
eurysms represent themost severe phenotypic feature of EFEMP2
mutations, we chose to specifically analyze collagen biosynthesis
and maturation in the aortic wall.
Results
Fibulin-4 loss alters fibrillar collagen protein expression
and localization but not gene expression
Since type I, III and IV collagens represent themost abundant col-
lagen subtypes in the aortic wall, we performed gene expression
analysis and immunofluorescent staining of P90 aortas of wild-
type (WT; Efemp2+/+;SM22-Cre) mice and mice specifically lacking
fibulin-4 in vascular SMCs (Efemp2loxP/KO;SM22-Cre; termed SMKO;
Ref. 9). QPCR did not show any difference in Col1a1, Col3a1 or
Col4a1 gene expression (Fig. 1A). Immunofluorescent staining,
however, revealed alterations in fibrillar collagen localization.
The majority of type I and III fibrillar collagens were found in
the adventitial layer in WT aortas, but in aortas of SMKO mice
both of these collagens appeared less prominently in the adven-
titial layer but were increased in the medial layer (Fig. 1B). This
was consistent with previous data showing an increase in type
I collagen levels in SMKO aortas by western analysis (27). Type
IV collagen showed variable expression levels in SMKO aortas
but was consistently found in the basement membrane sur-
rounding the SMCs in both control (n = 7) and SMKO (n = 11) aor-
tas. Overall, the protein was more disorganized in SMKO aortas,
likely due to the SMC disarray in these aortas (data not shown)
(9). Since type V collagen acts as an initiator of fibril assembly
(28) and regulates the number and size of collagen fibrils present
(29,30), we also examined type V collagen expression in the aortic
wall, but did not find any difference in localization or expression
levels by immunofluorescence in SMKO aortas compared with
WT (Supplementary Material, Fig. S1A).
We sought to determine differences in organization and
structure of fibrillar collagens in SMKO aortas. Second harmonic
generation (SHG) imaging provides amethod for specific imaging
of fibrillar collagen (mainly type I collagen) without the use of
antibodies and provides higher resolution imaging than is avail-
able with antibody labeling (31). Furthermore, SHG and two-
photon-excitedfluorescence (TPEF) have been shown to be highly
effective for simultaneously analyzing collagen and elastin, re-
spectively, in the aortic wall (32,33). In WT aortas, SHG signal
(green) was strongest in the adventitia, but in SMKO aortas,
strong SHG signal extended past the adventitiawell into themed-
ial layer containing fragmented elastic fibers (TPEF signal, red),
similar to the collagen localization pattern observed by immuno-
fluorescence (Fig. 1C). Collagen bundles in ascending aortas of
P90 mice appeared disorganized in SMKO, in contrast to those
seen in WT mice, particularly in the adventitia, which were
aligned in a wave-like pattern. Additionally, the increased punc-
tate appearance of the collagen was suggestive of decreased
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collagenmaturity. Thus, loss of fibulin-4 leads to disorganization
and redistribution of fibrillar collagen in the aortic wall.
Fibulin-4 loss decreases collagen content andmaturation
The final step in collagen maturation is cross-linking, a multi-
step process initiated by the lysyl oxidase family of enzymes.
Since others have shown that fibulin-4 directly interacts with
LOX, and our SHGdatawere suggestive of immature and/or disor-
ganized collagen fibers, wehypothesized thatfibulin-4 lossmight
lead to a decrease in LOX-mediated collagen cross-linking. We
performedHPLC analysis on P90 aortas and found a 23% decrease
in mature collagen cross-linking, pyridinoline (Pyr) in SMKO
compared with WT, which was statistically significant (Fig. 1D).
Deoxypyridinolinewas not quantified due to the limited quantity
in these samples. Surprisingly, however, despite the appearance
of more collagen in the aortic wall via immunofluorescence,
we found a 16% decrease in collagen content measured as
hydroxyproline/total protein in SMKO aortas compared with
WT (P < 0.001) when normalized to total amounts of protein
(Fig. 1E). We also previously showed aortic wall thickening in
SMKOmice, and thus it is possible that the increase in other ves-
sel wall components results in a net decrease in collagen content
in our calculations (9). Thus, in the SMKO aortic wall, not only is
relative collagen content lower, but the content of mature cross-
link per collagen is also diminished in comparison with WT.
Since LOX also catalyzes the cross-linking of elastin, we ana-
lyzed two of the elastin-specific cross-links, desmosine and iso-
desmosine, in aortas. In contrast to collagen cross-links, we
found a significant increase in both desmosine and isodesmosine
in SMKO, indicating that the loss of fibulin-4 selectively leads to
decreased collagen but not elastin cross-linking, despite clear
disruption of elastic fiber structure (Fig. 1F and G). This is in
sharp contrast to a Lox-null mouse model, in which desmosine
content was decreased by ∼60% (34).
Aortic collagen fibril diameter is increased and fibril
organization is highly disrupted
The decrease inmature collagen, alongwith the appearance of ab-
normal collagen structure via SHG imaging, led us to examine the
structural defects in collagen in greater detail. Electronmicroscopy
(EM) of the thoracic aorta showedhighly irregular collagen fibrils in
the SMKOcomparedwithWTat P90, a timepointwhenaneurysms
are fully established (Fig. 2A and B). Collagen fibril size was highly
variable in SMKO aortas, with numerous large fibrils as well as
some that were abnormally small in size. Additionally, fibrils in
SMKO aortas exhibited profound disorganization and appeared
more loosely packed than those inWT aortas. Quantification of fi-
bril diameter confirmed a wider distribution of fibril diameters in
SMKO compared with WT aortas, along with an overall increase
in fibril size, which was statistically significant (48.89 ± 10.03 nm
Figure 1. Loss of fibulin-4 leads to alterations in collagen localization, organization and cross-linking but not gene expression. (A) Quantitative PCR of Col1a1, Col3a1 and
Col4a1 showed no difference in gene expression in smoothmuscle-specific knockout (Efemp2loxP/KO;SM22-Cre; termed SMKO) versus wild-type (Efemp2+/+;SM22-Cre; termedWT)
aortas (n = 3). (B) Collagen type I (Col I) and type III (Col III) are increased in themedial layer of SMKO ascending aortas, whereas themajority of these proteins are found in
the adventitia ofWTmice. Scale bar represents 50 µm.WT, n = 3; SMKO, n = 4 aortas. Samples are oriented with the vessel lumen at the top and adventitia on the bottom.
(C) SHG (green) imaging of collagen fibers and two-photon imaging of elastic fibers (TPEF; red) confirm an increase of fibrillar collagen in the medial layer of SMKO aortas
and indicate a disorganization of collagen fibers in SMKO. Scale bars represent 50 µm. White dotted lines in lower panels denote medial layer. N = 3 aortas per genotype.
(D) HPLC analysis ofmature collagen cross-links showed a 23% decrease in cross-linking in SMKO comparedwithWT. (E) HPLC analysis of collagen content (normalized to
amounts of total protein present in each sample) showeda significant decrease in collagen in SMKOaortas (FandG). Desmosine (F) and isodesmosine (G)were increased in
SMKO aortas compared with WT using a Student’s t-test. In (D–G), n = 4 for each genotype; *P < 0.05, **P < 0.01, ***P < 0.001.
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inWT versus 77.73 ± 34.75 nm in SMKO; P < 0.0001; Fig. 2C). In add-
ition to highly variable (but overall larger) fibril diameters, disor-
ganization of fibrils and decreased bundle density were observed
in SMKO compared with smooth and homogenous fibrils seen in
WT, suggesting that one ormoremolecules involved in controlling
fibril shape and/or sizemayalso be affected by fibulin-4 loss. Inter-
estingly, fibulin-5 deficiency, which also leads to elastic fiber de-
fects, does not induce disruption in collagen fibrils (unpublished
observations), suggesting that loss of elastic fiber integrity alone
may be insufficient to drive the observed collagen defects. Based
on the appearance of loosely packed collagen fibrils, we examined
other non-collagenous ECM components to determinewhether an
increase in any of these componentsmay contribute to the altered
fibril density. Increased proteoglycan accumulation is a hallmark
feature of aortic aneurysms, and Alcian blue staining showed an
increase in glycosaminoglycan associated with proteoglycans in
SMKO aortas compared with WT (Supplementary Material,
Fig. S1B). It is possible that proteoglycan accumulation contributes
to the decreased fibril density. Fibronectin 1 forms a critical scaf-
fold for other ECM proteins, including fibrillar collagen and fibrillin
(35,36); therefore, we also examined fibronectin 1 expression and
localization, but foundnodifference betweenWTandSMKOaortas
(Supplementary Material, Fig. S1C).
LOX gene expression but not LOX processing is altered
in vivo, and LOX activity is decreased in matrix and
conditioned media in vitro
We next sought to determine the mechanism(s) driving the ob-
served collagen defects in SMKO aortas. Since fibulin-4 is known to
interact directly with LOX and many phenotypic similarities exist
between conventional Efemp2-null and Lox-null mice (8,34,37), we
analyzed LOX expression, localization, processing and activity in
vitro and in vivo. LOX activity in conditioned media from Efemp2
germline knockout (Efemp2−/−; termed GKO) mouse embryonic
fibroblasts (MEFs) was decreased by 35.49 ± 10.72% compared with
Efemp2+/+ littermate controls (WT), which was statistically signifi-
cant (P < 0.05; Fig. 3A). Analysis of ECM extracts from bothWTand
GKO samples yielded similar results, with a slight decrease in LOX
activity per micrograms of total protein in GKO extracts compared
with WT, although this did not reach statistical significance
(Fig. 3B).
Full-length pro-LOX is inactive but is activated by proteolytic
cleavage of the propeptide region; therefore, detecting LOX
propeptide can provide an indirect estimate of the amount of
cleaved (active) LOX present in tissue samples. Immunofluores-
cent labelingwith an antibody directed against the propeptide re-
gion of LOX (LOX-pp) showed similar localization of LOX-pp
throughout the aortic wall in both control (Ctl; Efemp2+/+;SM22-Cre
or Efemp2KO/+;SM22-Cre) and SMKO P30 aortas, with increased ex-
pression in SMKO (Fig. 3C). Since immunofluorescence only
showed the total amount of LOX-pp (both cleaved from LOX
and uncleaved), we performed immunoblotting on aortic tissue
extracts and found a significant increase in total LOX (cleaved +
uncleaved) in SMKO aortas (Fig. 3D). The amount of full-length
LOX was also significantly increased in SMKO. We did observe a
slight decrease in the calculated percentage of cleaved LOX-pp
versus uncleaved LOX, but this did not reach statistical signifi-
cance, and the fact that both full-length LOX and LOX-pp were
increased in SMKO aortas suggests that greater amounts of active
LOX should be availablewithin the aorta of SMKOand that the de-
creased collagen cross-linking is not due to a simple loss of LOX
activity (Fig. 3E).
It is surprising that despite the striking disorganization of col-
lagen in the SMKO aortas, along with many phenotypic similar-
ities between the Lox-null mice and Efemp2-null mice, the
observed decrease in LOX activity does not appear to match the
amount of decrease in LOX activity in the Lox-null mice (17).
These data therefore imply that while a decrease in LOX activity
may be partially responsible for the collagen defects in SMKO
mice, additionalmechanisms also play an important role in colla-
gen synthesis andmaturation in SMKOaortas. It is also interesting
to note that despite decreased LOX activity in GKO conditioned
media and ECMextracts,wedid not observe increased LOXexpres-
sion by immunofluorescence or immunoblotting and did not de-
tect a difference in LOX cleavage (SupplementaryMaterial, Fig. S2).
Figure 2. Fibulin-4 loss leads to disorganized collagen fibrils with irregular shape and increased size (A and B). EM images showing collagen fibrils in P90 WT and SMKO
aortas. Note highly irregular and disorganized collagen fibrils in SMKO. Higher magnification images are shown in (B). Scale bars represent 500 nm. (C) Quantification of
fibril diameter showed awider distribution of fibril size in SMKO aortas, consistent with visual observations. Mean diameter of fibrils was significantly increased in SMKO.
One thousand fibrils from each genotype (500 fibrils each from n = 2 aortas) were measured.
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Multiple proteins involved in the collagen maturation
process are putative fibulin-4-interacting proteins
To identify binding partners of fibulin-4 that are potentially
involved in collagen maturation, we used affinity purification
and mass spectrometry. Rat vascular SMCs were infected with
adenovirus containing either fibulin-4 with a C-terminal V5 tag
(Ad5-fib4-V5) or control adenovirus containing GFP (Ad5-GFP)
with MOI 200. Two days after infection, the cells were incubated
for 18 h in 2% fetal bovine serum (FBS), and conditioned media
and cell lysates were harvested. Since immunoprecipitation
may fail to detect weaker and/or more transient protein–protein
interactions, proteins were reversibly cross-linked to preserve
Figure 3. LOX activity is decreased in vitro but LOX cleavage is normal in vivo. (A) LOX activity was significantly decreased in conditioned media from GKO MEFs, *P < 0.05.
(B) LOX activity was also slightly decreased in ECM extracts from GKO MEFs (not significant). Values were obtained by subtracting the amount of fluorescent signal
inhibited by the LOX inhibitor βAPN from the total amount of fluorescent signal for each sample. (C) Immunofluorescent staining using a LOX-pp antibody that
recognizes both cleaved and uncleaved LOX showed increased staining intensity in P30 SMKO aortas. Scale bar represents 50 μm. (D) Immunoblot showing both
uncleaved LOX and LOX propeptides are increased in SMKO aortas. Representative immunoblot data are shown; n = 6 WT and n = 9 SMKO aortas were used for
quantification and analysis. (E) Quantification of immunoblot in (D). Total LOX and full-length (uncleaved) LOX were significantly increased in SMKO aortas. LOX
propeptide (LOX-pp) was increased and the calculated percentage of cleaved LOX was slightly decreased in SMKO aortas, but were not statistically significant. Error
bars represent ±SD. **P < 0.01, ***P < 0.001.
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these interactions (38). Concentrated media and cell lysate were
immunoprecipitated with V5 antibody and run a short distance
onto a polyacrylamide gel. Entire bands were excised and sub-
jected to mass spectrometric analysis. We obtained a number
of potential interacting proteins that are known to be directly in-
volved in regulating collagen synthesis, maturation and assem-
bly, including Pcolce, Col1a1, Col2a1 and fibromodulin, an SLRP
(Table 1). Several proteins known to interact directly with fibu-
lin-4, including elastin and LOX, were also identified by the
screen, confirming the validity of the results (Supplementary
Material, Tables S1 and S2).
Fibulin-4 directly interacts with Pcolce but does not affect
Pcolce activity in vitro
Cleavage ofN- andC-terminal propeptides is an important regula-
tory step in collagen processing and assembly into fibrils, and pro-
blems with either of these steps lead to defects in fibril formation.
Cleavage of the C-terminal propeptide is mediated by BMP1, and
this reaction is enhanced by Pcolce. Since Pcolce was identified
by our proteomic screen as a potential fibulin-4 binding partner,
we performed solid-phase binding assays using commercially
available Pcolce (R&DSystems, Inc.) andpurifiedfibulin-4 contain-
ing a C-terminal V5-His tag (fibulin-4-V5) as a soluble ligand
(SupplementaryMaterial, Fig. S3A andB). Solublefibulin-4 showed
moderate binding to Pcolce in a dose-dependentmanner (Fig. 4A).
Tropoelastin was used as a positive control and showed a similar
binding pattern to fibulin-4 as Pcolce (Fig. 4B).
Based on the observed interaction, we hypothesized that fibu-
lin-4 might act as an enhancer of Pcolce activity and that its loss
might therefore lead to a disruption of C-terminal propeptide
cleavage. BMP1 and Pcolce were incubated in the presence or ab-
sence of fibulin-4 for 45 min at 37°C, with short forms of either
collagen I or III containing intact N- and C-terminal domains
(R&D Systems) as a substrate. Uncleaved short collagen type I
was slightly decreased and C-propeptide was increased by incu-
bation with BMP1. Based on silver staining, in the presence of
Pcolce, uncleaved collagen type I was significantly decreased
and cleaved C-propetide was increased: however, the cleavage
was not further enhanced by the presence of fibulin-4 (Fig. 4C
and D; compare lanes 3 and 5 in Fig. 4C). It has been shown
that heparin potentiates BMP1 and Pcolce-mediated cleavage of
short type I collagen in vitro (39), and both Pcolce and fibulin-4
have been shown to bind heparin (40,41). However, fibulin-4 did
not exhibit any effects on the cleavage of short type I collagen
in either the presence or absence of heparin (Fig. 4C and D).
Similar results were obtained using short type III collagen as a
substrate (Supplementary Material, Fig. S3C and D). We also
Table 1. Potential fibulin-4-interacting proteins identified by mass spectrometry






Function in collagen regulation References
Collagen α1(I), α2(I) 30, 41 35.3, 43.2 Highly abundant collagen in aortic wall (65)
Serpin H1 (Hsp47) 16 41.2 Collagen protein folding in ER (66)
Procollagen C-endopeptidase
enhancer 1
7 20.3 Enhances BMP1-mediated C-propeptide
cleavage
(67)
Fibromodulin 8 27.9 Fibril size/organization (44)
Biglycan 3 7.6 Fibril size/organization (57)
Lactadherin 10 22.2 Collagen removal from tissue (68)
Lysyl oxidase 9 35.5 Collagen cross-linking (69)
Figure 4. Fibulin-4 interacts with Pcolce but does not affect its activity in vitro.
(A and B) Fibulin-4 binds to Pcolce (A) and tropoelastin (B). Representative solid-
phase binding assay using Pcolce or tropoelastin as the solid-phase and
increasing concentrations of fibulin-4 as soluble ligand. Bovine serum albumin
(BSA) was used as a negative control, and data are shown with values for BSA
binding subtracted from the final values. N> 3 independent experiments. (C and D)
Pcolce enhances BMP1-mediated cleavage of a short form of the α1 chain of type I
collagen, but adding fibulin-4 does not further enhance the cleavage, either in
the presence or absence of heparin. Representative silver stain is shown in (C),
and quantification of n = 3 independent experiments is shown in (D). Error bars
represent ±SEM. Similar results were observed using a short form of Col3a1
(Supplementary Material, Fig. S3C and D). Asterisk denotes fibulin-4.
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performed immunofluorescent staining and observed Pcolce ex-
pression in both WT and SMKO aortas, although Pcolce staining
appeared stronger toward the outer medial layer and adventitial
layer of SMKO aortas (Supplementary Material, Fig. S4). Thus,
fibulin-4 binds Pcolce but may play more of a role in localization
of Pcolce rather than directly affecting Pcolce/BMP1-mediated
C-terminal collagen propeptide cleavage in vitro.
Discussion
Our results show that fibulin-4 is important for the integrity of
collagen in the aortic wall, in addition to its already well-estab-
lished role in elastic fiber formation. Specifically, we found that
the loss of fibulin-4 in vascular SMCs leads to accumulation of
collagen fibers in the aortic media that are highly disorganized
and irregular in shape and size. In contrast, deletion of fibulin-5,
which also disrupts elastic fibers in the aortic wall, does not affect
collagen, suggesting that fibulin-4 plays a non-redundant role in
maintaining collagen integrity in the vessel wall. Furthermore,
alterations in fibril size and shape have been observed in other
mouse models and in human disease, including decorin-, lumi-
can- and fibromodulin-deficient mouse models (42–44), classical
Ehlers-Danlos Syndrome Type I and II (45), Ehlers-Danlos Syn-
drome type VIIA and VIIB (46) and Osteogenesis Imperfecta
(47,48), providing evidence that the structural changes observed
in SMKO mice are likely to be biologically relevant.
Among 29 collagen types, there are 7fibrillar collagens (I–III, V,
XI, XXIV and XXVII), with types I and III being themost abundant
collagens in the aorta (49). Collagen fibrils are organized into fiber
bundles arranged in a parallel manner in normal aortas (50) and
provide tensile strength to the vessel wall (51). Although fibulin-4
has been shown to interact with type IV collagen, we did not
observe differences in type IV collagen localization and failed to
find differences in expression levels between WT and SMKO aor-
tas. Surprisingly, there was no observed increase in Col1a1 or
Col3a1 gene expression, despite our previous observations of
increased angiotensin II and TGFβ1-dependent signaling, which
are known stimulators of collagen production in SMCs (52,53). It
is possible that other regulatory mechanisms control or limit the
accumulation of these mRNAs.
Contrary to our expectations and despite phenotypic similar-
ities between Efemp2-null and Lox-null mice, our data suggest
that the observed type I collagen defects are not solely attribut-
able to a loss of LOX activity. We found an overall 16% decrease
in total collagen content in SMKO mice, compared with a ∼25%
decrease in Lox-null aortas, as measured by hydroxyproline con-
tent (34). Furthermore, we found a 23% decrease in mature colla-
gen cross-link, pyridinoline, when normalized to collagen. This
implies that not only is overall collagen content decreased, but
cross-linking ‘in’ collagen is also defective. Thus, the net effect
of these decreases on mechanical properties of the aorta could
be significant. We further found a decrease in LOX activity in
both MEFs and ECM extracts from MEF cells in culture, although
the latter failed to reach statistical significance. In contrast,
Lox-null mice displayed a large decrease in immature collagen
cross-links [43% reduction in DHLNL (dihydroxylysinonorleu-
cine), and 39% reduction in HLNL (hydroxylysinonorleucine)]
and an ∼80% decrease in LOX activity in cultured SMCs (17,34).
Additionally, we found that LOX expression was increased
in vivo, and LOX was cleaved nearly as efficiently in SMKO aortas
as in WT with a small decrease that did not reach statistical
significance. It has previously been shown that fibulin-4 binds
LOX-pp and suggested that fibulin-4 plays a role in LOX localiza-
tion for proper function in elastin cross-linking (7). Interestingly,
cross-linking of elastin was not decreased in SMKO aortas but
was even paradoxically increased. This is in sharp contrast to
Lox-null mice, in which desmosine content was reduced by
∼60% (34). Although collagen fibrils appear disorganized in
other tissues via EM analysis in Lox-nullmice, one study reported
no difference in collagen fibril diameters in the Lox-null aortas, in
direct contrast to the significant increase in fibril size and broader
distribution of fibril diameters observed in SMKO aortas (34).
Thus, collagen was severely disorganized in SMKO aortas, but
cross-linking and loss of LOX activity were not as severe as in
Lox-nullmice. These differences suggest that additionalmechan-
isms may control fibril size and organization in SMKO aortas.
Further investigation of the mechanism(s) driving the colla-
gen defects led us to examine Pcolce identified through our
Co-IP and proteomic screening. Solid-phase binding assays con-
firmed binding between fibulin-4 and Pcolce, although binding
was less strong than reports showing fibulin-4 binding to elastin
or LOX. Surprisingly, however, fibulin-4 did not affect the ability
of Pcolce to enhance BMP1-mediated cleavage of the procollagen
C-terminal propeptide in either the presence or the absence of
heparin in cleavage assays. Together with the finding that total
loss of Pcolce in mice leads to collagen fibril abnormalities in
multiple tissues including bone and tendon (54), our data suggest
that the role of fibulin-4 in collagen fibrilmaturation is not direct-
ly potentiating the function of Pcolce, but rather serving as an
important scaffolding protein to bring Pcolce and LOX in close
proximity to ensure efficient collagen cross-linking during fibril-
logenesis (Fig. 5). Accordingly, the function of fibulin-4 may be
more critical in conditions in which collagen turnover and/or
remodeling increases such as hypertension or aneurysm expan-
sion (55,56). Since BMP1 cleaves LOX in addition to fibrillar colla-
gen, it is also possible that the absence of fibulin-4 may liberate
more Pcolce and enhance BMP1-mediated collagen cleavage but
decrease BMP1-mediated LOXmaturation, resulting in inefficient
collagen fibril formation.
Figure 5.Model: Fibulin-4 as a scaffolding protein for proper localization of Pcolce
in addition to LOX. We propose a role for fibulin-4 in stabilization of Pcolce/
procollagen complex for BMP1 cleavage of collagen C-terminal propeptide,
similar to a previously published proposal for heparin interaction with Pcolce,
collagen, heparan sulfate proteoglycans and BMP1 (39). In the absence of
fibulin-4, this localization is likely disrupted.
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In future studies, it would be interesting to determine
whether fibulin-4 plays a role in correct localization of other pro-
teins. Additionally, it will be fascinating to observe whether
interaction of fibulin-4 and Pcolce (and potentially other proteins
involved in collagen regulation) plays an important role in other
tissues such as tendons and ligaments, where collagen content is
much higher than in the vessel wall. Results from our proteomic
screen suggest that fibulin-4may interact with one ormore of the
SLRPs, which could in turn contribute to the observed collagen
defects. Mice lacking biglycan, an SLRP, develop irregular colla-
gen fibrils similar to what we observed in SMKOmice, and aortas
spontaneously rupture in males when mice are ∼3 months old
(57). Loss of other SLRPs, including fibromodulin, decorin and lu-
mican, or a combination of these proteins, also lead to disrup-
tions in collagen fibrillogenesis (42–44). Fibromodulin was
recently shown to inhibit LOX-mediated cross-linking on the
C-telopeptide of collagen, suggesting a mechanism by which fi-
bromodulinmayhelp prevent prematurefibril assemblyand con-
strain fibril growth (58). It will be interesting to see in future
studies whether fibulin-4 interacts with these SLRPs.
In summary, we have expanded the interaction network of
fibulin-4 to include Pcolce and characterized a previously unstud-
ied role for fibulin-4 in regulating collagen maturation in the
vascular wall. Given the wide array of abnormalities in both col-
lagen- and elastin-rich tissues observed in patients with EFEMP2
mutations, our study suggests that a more detailed analysis of
collagen in other tissues affected by the loss of fibulin-4 would
prove useful, both for gaining a better understanding of the
underlying pathologic mechanisms and for developing more ef-
fective ways to treat these and other connective tissue disorders.
Materials and Methods
Mice
All mouse studies were approved by the University of Texas
Southwestern (UTSW) Medical Center Institutional Animal Care
and Use Committee. Animals were housed in the UTSWAnimal
Resource Center, and all procedures were carried out in accord-
ance with NIH Guidelines for the Care and Use of Laboratory
Animals. Smoothmuscle-specific and germline Efemp2 knockout
micewere generated as described previously (RRID:MGI_4947945;
Tg(CAG-cre)13Miya;Efemp2tm1.Hiya/Efemp2tm1.Hiya and Tg(Tagln-
cre)1Her;Efemp2tm1.1Hiya/Efemp2tm1.2Hiya) (9). Mice wild type for
Efemp2 but containing the Tagln-Cre (SM22-Cre) transgene
(Efemp2+/+;SM22-Cre) were used as WT for comparison with Efem-
p2loxP/KO;SM22-Cre (SMKO) mice. Mice heterozygous for Efemp2
containing the Tagln-Cre transgene (Efemp2KO/+;SM22-Cre) showed
no phenotypic differences as previously observed (59) and were
also included for comparison where indicated as Ctl.
Quantitative PCR
Whole aortas were carefully dissected from P90 SMKO and control
mice. Following tissue homogenization,mRNAwas isolated using
an RNeasy mini kit (Qiagen) and quantified on a Nanodrop. Equal
amounts ofmRNAwere reverse transcribed using an iScript cDNA
synthesis kit, and real-time PCR was performed using iTaq super-
mix containing SYBR green (Bio-Rad). QPCR primers used were as
follows: Col1a1 (CCAAGGGTAACAGCGGTGAA fwd; CCTCGTTTTCC
TTCTTCTCCG rev), Col3a1 (TCAAGTCTGGAGTGGGAGG fwd; TCCA
GGATGTCCAGAAGAACCA rev), Col4a1 (TACCATGGATACTCTCTGC
TCTATGTC fwd; TGCCAGCCGTACCCAAGT rev), Gapdh (AGTATG
ACTCCACTCACGGCAA fwd; TCTCGCTCCTGGAAGATGGT rev)
and B2M (CCGAGCCCAAGACCGTCTA fwd; AACTGGATTTGTAAT
TAAGCAGGTTCA rev). Data fromat least three aortasper genotype
were obtained andwere normalized toGapdh and β2Microglobulin
(B2M). Quantification was performed using the ΔΔCt method, and
datawere analyzed using a Student’s t-test, with P-values of <0.05
considered statistically significant.
Immunofluorescence and second harmonic generation
imaging
Phosphate-buffered saline (PBS)-perfused aortas were harvested
from P30 and P90 mice and immediately embedded in OCT for
cryosectioning. For two photon imaging, 20 µm transverse sec-
tionsweremounted on glass slides and kept frozen. Immediately
before imaging, samples were thawed to room temperature,
hydrated with PBS and coverslipped. SHG and TPEF were used
to visualize collagen and elastin, respectively, using a Zeiss
LSM780 microscope (Carl Zeiss Microscopy, Thornwood, NY,
USA) with a Chameleon Vision II Ti:Sapphire laser (Coherent,
Inc.). SHG and TPEF were excited at 810 nm and imaged with a
LD C-Apochromat ×40/1.1 W Korr objective lens. Backscattered
SHG was separated from TPEF using a 380-430/470-520 filter set
(Zeiss LSM BiG 1756-082) and detected with a non-descanned
GaAsP detector.
For lysyl oxidase, type V collagen and Pcolce immunostaining,
10 µmcryosectionswerefixed for 10 min in 4%PFA, blocked1 h in
5% normal goat serum and incubated with primary antibody
[LOX-pp (1:100; kindly provided by P. Trackman) (60), type V colla-
gen (1:100; Novus Bio no. NBP1-19633) or Pcolce (1:100; MyBio-
Source no. MBS2004251)] overnight. Sections were incubated
with an AlexaFluor 568-conjugated secondary antibody (1:200;
Invitrogenno. A-11011). SectionsweremountedwithVectashield
mounting medium with DAPI (Fisher, no. H-1200) and imaged
using either an Axio Observer (Zeiss) for non-confocal imaging
or either a Zeiss LSM500 or Nikon A1R microscope for obtaining
confocal images. For collagen I, III and IV and fibronectin-1 im-
munostaining, P90 aortas were perfused with PBS followed by
4% PFA, fixed overnight at 4°C in 4% PFA and processed for paraf-
fin embedding. Five-micrometer sections were mounted on
slides, deparaffinized and rehydrated through a series of alco-
hols. Antigen retrievalwas performedusing sodiumcitrate buffer
(pH = 6.0). Sampleswere blocked in 10%normal goat serum+0.3%
Triton-X-100 for 1 h, followed by type I or III collagen (Abcam no.
ab34710 and no. ab7778, respectively, 1:100), type IV collagen
(Millipore Ab756P, 1:100) or fibronectin-1 (Abcam no. ab6328,
1:100) antibodies overnight at 4°C. The appropriate secondary
antibody (AlexaFluor 488, 1:100; Invitrogen no. A11001 or no.
A11008) was incubated for 1 h followed by DAPI (1:100; Sigma
no. D9542) for 30 min, and sections were mounted with 50% gly-
cerol/50% phosphate-buffered saline prior to imaging using an
Axio Observer microscope. SHG/TPEF and confocal images were
processed and analyzed using Zen software (Zeiss) or NIS Ele-
ments (Nikon). For non-confocal fluorescence microscopy,
images were analyzed using Axiovision software (Zeiss).
Collagen and elastin cross-linking analysis
and collagen quantification
Ascending aortas from P90 mice (n = 6 per genotype; three sam-
ples were pooled for one part of the analysis, and for the other
part of the analysis, three samples were analyzed individually,
for afinal n of 4 independent runs)were pulverized in liquid nitro-
gen, washed with cold PBS then with distilled water and lyophi-
lized. An aliquot of each (∼1 mg) was hydrolyzedwith 6NHCl and
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subjected to amino acid and cross-link analyses as previously de-
scribed (61). The collagen content was estimated as a percent of
collagen in total protein based on the value of 100 residues of hy-
droxyproline per 1000 amino acids in collagen. The amounts of
pyridinoline and deoxypyridinoline were expressed as moles/
mole of collagen. Desmosine and isodesmosine content was
also quantified as nanomolar concentrations per 1000 amino
acids.
EM and quantification of collagen fibril size
P90 SMKO and WT mice were perfused with PBS to clear blood,
followed by 3% glutaraldehyde in 0.1% sodium cacodylate (pH =
7.4) to fix the tissues. Following dissection, aortas were fixed fur-
ther overnight. Aortas were treated sequentially with osmium
tetroxide, tannic acid anduranyl acetate anddehydrated and em-
bedded in Epon as previously described (62). Sixty-nanometer
sections were counterstained with 7%methanolic uranyl acetate
and lead citrate and observed using Tecnai 12 transmission elec-
tronmicroscope operating at 120 kV. All images were obtained at
×13 000 magnification and were analyzed using ImageJ software
(NIH). Images were calibrated so that each image contained 500
pixels/nm. To reduce background noise and facilitate quantifica-
tion of individual collagen fibrils, the threshold of each image
was uniformly adjusted to mid-gray. For quantification of fibril
size, 500 fibrils were randomly selected for quantification
from each mouse, for a total of 1000 fibrils per genotype. Fibril
diameter was calculated from the area using the following
formula, D =√(A/π). Statistical analyses were performed using
GraphPad Prism software. A Student’s t-test was used to deter-




Adenoviruses containing either fibulin-4 with a C-terminal V5
tag (Ad5-fib4-V5) or GFP (Ad5-GFP) were generated and titrated.
Primary rat aortic SMCs (Lonza no. R-ASM-580) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing 20%
FBS, 20 m HEPES, 1 m sodium pyruvate, antibiotic/antimyco-
tic, 2 m -glutamine, ITS supplement (Sigma no. I3146–5 ml),
20 ng/ml basic fibroblast growth factor and 5 ng/ml epidermal
growth factor. Cells at ∼50–60% confluence were treated with ei-
ther Ad5-fib4-V5 or Ad5-GFP at a range ofMOIs (100–1000), and an
optimal MOI was determined at 48 h post infection. MOI 200 was
selected as the minimum dose required to obtain 95–100% GFP-
positive cells. Rat SMCs were incubated with Ad5-fib4-V5 or Ad5-
GFP for 16–18 h and washed with PBS, and fresh culture media
were added. Two days after infection, the cells were incubated
for 18 h in 2% FBS. Conditionedmediawere collected and concen-
trated using centrifugal concentrators (Millipore, 3000 MWCO).
Cell layers were washed with PBS, and reversible cross-linking
was performed prior to cell lysis (38). Briefly, dithiobis(succinimi-
dyl propionate) (DSP) and dithiobismaleimidoethane (DTME)
were used as reversible cross-linkers and were chosen based on
their ability to cross-link lysine and cysteine residues, respective-
ly (Fisher Scientific). Cells were treated with increasing doses of
either DSP or DTME (0.1, 0.5 and 1 m) for 30 min. Cell layers
were then washed 2× in PBS and treated with Stop solution
(Tris–HCl + -cysteine) for 10 min on ice. Cell layers were washed
1× in PBS, scraped in RIPA buffer, placed in 1.5 ml tubes and
passed through a 23-gauge needle to shear DNA. Cell lysates
were then centrifuged at 13 000 rpm for 30min at 4°C. Supernatants
were run under both non-reducing and reducing conditions and
immunoblotted with V5 antibody (Invitrogen/Life Technologies
no. R960-25, 1:5000) followed by secondary antibody (goat anti-
mouse HRP 1:5000, PerkinElmer no. NEF822) to determine the op-
timum dose for each cross-linker and confirm that cross-linking
could be reversed via dithiothreitol (DTT) treatment. For prote-
omic analysis, cells were treated simultaneously with 0.5 m
DSP and 0.1 m DTME as described above.
Concentratedmedia and cross-linked cell lysateswere immu-
noprecipitated with V5 antibody (Invitrogen/Life Technologies
no. R960-25, 1:250). Cell lysates were treated with DTT to remove
the reversible cross-links. Immunoprecipitated samples were
run 5–10 mm onto a polyacrylamide gel, stained with Coomassie
and partially destained to reveal a single large protein band. En-
tire gel bands were excised and submitted to the Proteomics Core
at UTSW for analysis.
Protein purification
Full-length mouse fibulin-4 including the 5′ UTR was cloned by
PCR and ligated into a pcDNA5/FRT/V5-His-TOPO vector (Invitro-
gen). The fibulin4-V5 vector was co-transfected with a second
vector containing Flp recombinase (pOG44, Invitrogen) into Flp-
InTM-CHO cells as previously described (14). Cells overexpressing
fibulin-4-V5 were selected using hygromycin and conditioned
media were harvested. Proteins were precipitated using ammo-
nium sulfate and were dialyzed against PBS. The sample was
run through a Nickel column (GE Healthcare) and fractions con-
taining fibulin-4 were then passed through a column containing
Q-sepharose (GE Healthcare). Q-column fractions containing fi-
bulin-4 were then passed through a Cobalt column and desalted
(PD10 columns; GE Healthcare). The resulting protein was >95%
pure based on silver staining. Full-length mouse Pcolce was
cloned from mouse liver cDNA into pFLAG-CMV™-3 (Sigma)
and stably overexpressed in CHO-K1 cells. Following ammonium
sulfate precipitation and dialysis against PBS, NaCl and ethylene-
diaminetetraacetic acid (EDTA) were added to a final concentra-
tion of 400 m and 10 m, respectively. Protease inhibitor
cocktail (Sigma) was also added to the sample. The sample was
applied to a 0.6 ml FLAG column (Sigma), washed with buffer
containing 50 m HEPES, 150 m NaCl, and 0.01% brijL23, and
eluted with 0.1  glycine-saline 0.01% BrijL23 (pH3.0). Tris–HCl
(pH.8.0) was added to adjust the sample pH. To eliminate FLAG
antibody contamination, elutants were added to the solution
with a final concentration of 100 µg/ml 3xFLAG peptide, 0.05%
TX-100 and 0.01% brijL23, and then applied to a Protein G column
(0.5 ml; GE Healthcare). Samples were eluted from the column
with buffer containing 50 m Tris–HCl (pH7.5), 250 m NaCl,
0.05% TX-100 and 0.01% brijL23. Sample purity was assessed via
immunoblotting and silver stain.
Solid-phase binding assays
Solid-phase binding assays were carried out as described previ-
ously (14,63). Briefly, proteins (10 µg/ml) were coated in 96-well
plates (Nunc) at 10 µg/ml at 4°C overnight. Plates were blocked
in TBS-T containing 5% non-fat drymilk at 4°C overnight. Soluble
ligands were added to the plates and incubated for 3 h at room
temperature, washed 5× in TBS-T containing 0.025% tween-20
and 2 m CaCl2. Plates were incubated with primary V5 antibody
for 1.5 h (1:5000; Invitrogen no. R960–25), washed and incubated
with anti-mouse HRP (1:2500; Bio-Rad no. 170-6516) for 1 h at
room temperature. TMB substrate (R&D Systems no. DY999)
was incubated for 20 min, and the reaction was stopped with
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2 N H2SO4. Plates were read at 450 nm using an Optima Fluostar
plate reader (BMG Labtech). Data were analyzed using Graphpad
Prism software.
Tissue protein extraction and immunoblotting
Ascending aortaswere harvested and snap frozen. Tissue protein
was extracted using RIPA buffer with protease and phosphatase
inhibitors added (Sigma), homogenized in RIPA buffer using a
Bullet blender (NextAdvance, Inc.) and centrifuged to clarify
lysates. Equal amounts of protein were loaded onto agarose
gels, transferred to polyvinylidene difluoridemembrane, blocked
for 1 h in 5% milk in TBS-T and incubated with primary antibody
followed by either rabbit or mouse secondary antibody at a 1:2000
dilution (PerkinElmer, NEF812 and NEF822, respectively). The fol-
lowing primary antibodies were used: LOX-pp (1:1000; kindly pro-
vided by P. Trackman; Ref. 60), Pcolce (1:200; Sigma no. C2122) and
Gapdh (1:1000, Cell Signal no. 2118L). Immunoblots were quanti-
fied using ImageJ software, and data were analyzed using Graph-
pad Prism software.
MEF isolation and culture, and LOX activity assays
MEFs were isolated from Efemp2 WT and KO embryos at E12.5–
E14.5. The head and internal organs were removed, and the re-
maining tissue was homogenized using a syringe and 18-gauge
needle. Explants were grown in DMEM containing 10% FBS and
Pen/Strep (Invitrogen). All experiments were performed on
MEFs at Passage 2 or 3. LOX activity assays were performed as de-
scribed by Trackman PC et al. (64). Briefly, equal numbers of WT
and KO MEFs were plated in 10 cm dishes. At 70–80% confluency,
MEFs were placed in serum-free, phenol red-free DMEM over-
night (16 h). Conditionedmedia were collected and concentrated
40× using a 10000MWCO centrifugal filter (Vivaspin). ECM was
extracted in buffer containing 4 Urea and 0.05  borate. Follow-
ing brief sonication, lysates were clarified via centrifugation and
concentrated using 3000MWCO centrifugal filters (Millipore).
Samples were added to wells of a 96-well plate and were treated
±βAPN in quadruplicate. Samples were then incubated for 15 min
at 37°C in buffer with a final concentration of 1.2  Urea, 0.05 
borate (sodium tetraborate decahydrate, Sigma), 10 µ OxiRed
fluorescent probe (10-acetyl-3,7-dihydroxyphenoxazine; BioVi-
sion no. 1572-5), 10 m diaminopentane (Fisher no. 08730) and
2 U/ml HRP. Loxl2 (lysyl oxidase-like protein 2) protein was used
as a positive control (R&D Systems no. 2639-AO-010). Plates
were read at 544/590 nm using an Optima Fluostar plate reader
(BMG Labtech). LOX activity was calculated by subtracting the
amount of signal from βAPN-treated samples from untreated
samples. Experiments were repeated at least three independent
times. Purified Loxl2 protein (R&D Systems no. 2639-AO-010)
treated ±βAPN was used as a positive and negative control. Data
were graphed and analyzed using GraphPad Prism software, with
P < 0.05 considered statistically significant.
Pcolce-enhancing activity assays
Assays were performed as described elsewhere (39). Briefly, short
procollagen I(α1) containing intact N- and C-terminal propep-
tides (R&D Systems, no. 6220-CL-020) was incubated at a concen-
tration of 148 n with recombinant human BMP1 (11.9 n) and
Pcolce (54 n) in the presence or absence of fibulin-4 (40 n).
BMP1 and Pcolce were also purchased from R&D Systems
(no. 1927-ZN-010 and no. 2239-PE-020, respectively). Heparin
(50 µg/ml) was used as a positive control. Short type I or type III
collagen (R&D Systems, no. 6220-CL-020 and no. 7294-CL-020, re-
spectively) and Pcolce (± fibulin-4, ±heparin) were pre-incubated
for 1 h at 37°C. BMP1 was added, and the incubation was contin-
ued for an additional 45 min at 37°C. Samples were denatured
and separated by sodium dodecyl sulphate–polyacrylamide gel
electrophoresis, and proteins were visualized and quantified by
silver staining. Assayswere performed at least three independent
times, and data were analyzed using one-way ANOVA.
Supplementary Material
Supplementary material is available at HMG online.
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